Basecamp Research raised an oversubscribed $140 million Series C to train its EDEN biological foundation model and apply it to in vivo cell therapy design. The company is positioning EDEN as a platform for generating complex DNA sequences using serine recombinase-based delivery logic, with the aim of improving clinical feasibility and manufacturing economics. Basecamp said it has shown preclinical results across multiple modalities and disease areas, and it plans to continue building partnerships with biopharmas as it advances cell therapy candidates. The financing includes participation from Anthropic, alongside Nvidia-linked involvement, tying therapeutic design to frontier AI infrastructure. In the cell therapy space, the funding reinforces investor appetite for platform companies that claim faster translation from in silico design to biologically validated constructs.